ArticleACS omega2025
How the Universal MSA52 Aptamer Recognizes the SARS-CoV‑2 Spike Protein.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the COVID-19 pandemic. The prominent characteristic of SARS-CoV-2 is the use of a trimeric spike (S) glycoprotein to invade the host cell; therefore, the S protein has become a major drug and vaccine target. Recently, a universal aptamer (MSA52) has been reported to bind to the S protein of seven former variants of concern (VOCs) in both glycan and nonglycan forms. However, no molecular details regarding these interactions are currently available. Thus, in this work, molecular dynamics (MD) simulations were performed to understand the binding of MSA52 to the S protein in both its nonglycosylated (NG) and glycosylated (G) forms. In the NG, MSA52 is inserted between the receptor binding domain (RBD) and the N-terminal domain (NTD), whereas most parts of MSA52 were in contact with the RBD in the G form. This binding is observed to be driven primarily by electrostatic interactions. MSA52 seems to bind more tightly to NG than G. In G, not only protein components but also glycans interact with MSA52. MSA52 targets the RBD like other existing aptamers, but it binds to a conserved region, explaining its ability to recognize seven VOCs. Furthermore, MSA52 can bind both RBD-up and RBD-down conformations, which could be beneficial for the effective prevention of viral infection during different mechanistic stages. The molecular insights obtained here will be useful for the future design of more effective SARS-CoV-2 aptamer-based biosensors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.